We manufactured our validation batch the last week of June 2018. We manufactured a second batch of product in March 2019. We are planning a production run of three more batches. This work will give us five validation batches, which are needed for EPA filing.
We are currently in the process of putting together our EPA filing. We expect to file by Q4 2019.
We are interested in the following areas with our SpayVac pZP vaccine:
Although four studies demonstrate single-dose efficacy in both white-tail and fallow deer species, we would be interested in partnering with a group to optimize administration practices in deer. Please contact us if you are interested. email@example.com
Our goal is to develop a portfolio of vaccines. The priority populations for which we intend to expand our portfolio are:
These populations represent over 1,000,000,000 animals in overabundance. In some of these species we may be able to use SpayVac pZP our lead product. In other species we will formulate a different vaccine with a different antigen (active ingredient).